Literature DB >> 2559955

Improved sensitivity of detection by avidin-biotin complex (ABC) immunocytochemistry in Epstein-Barr virus serology.

S Y Thoe1, C K Sam, H M Cheng, U Prasad.   

Abstract

Serum antibodies against Epstein-Barr virus (EBV)-determined antigens have traditionally been titrated by the indirect immunofluorescence (IIF) technique. The avidin-biotin complex (ABC) immunocytochemical technique was used to determine the serum levels of IgA against EBV viral capsid antigen (IgA/VCA) and IgA against EBV early antigen (IgA/EA) in sera of 106 nasopharyngeal carcinoma (NPC) patients prior to treatment and 100 normal individuals. The sensitivity of the ABC technique is enhanced by an amplification of the antigen-antibody reaction, which involves the binding of the enzyme-linked ABC to the second biotinylated antibody. There was a good correlation (r = 0.9988) between ABC and IIF-determined IgA/VCA-positive titres, with the ABC technique being more sensitive than IIF in the detection of IgA/VCA in NPC sera: 94% (99/106) and 76% (80/106), respectively. The frequency of IgA/EA reactivity in NPC sera was also markedly increased by immunodetection with the ABC technique as compared with IIF technique: 63% (69/106) and 28% (30/106) respectively. Both the immunocytochemical techniques were equally specific in discriminating between elevated serum titres of IgA/VCA and IgA/EA in NPC sera from normal human sera.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2559955     DOI: 10.1002/jmv.1890290417

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  2 in total

1.  Clinical relevance of serum immunoglobulin A antibodies to Epstein-Barr virus envelope glycoprotein gp350 in nasopharyngeal carcinoma patients.

Authors:  J W Xu; A Ahmad; J Menezes; U Prasad
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

2.  A high incidence of serum IgG antibodies to the Epstein-Barr virus replication activator protein in nasopharyngeal carcinoma.

Authors:  A Mathew; H M Cheng; C K Sam; I Joab; U Prasad; C Cochet
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.